<code id='8A1F9AF0CA'></code><style id='8A1F9AF0CA'></style>
    • <acronym id='8A1F9AF0CA'></acronym>
      <center id='8A1F9AF0CA'><center id='8A1F9AF0CA'><tfoot id='8A1F9AF0CA'></tfoot></center><abbr id='8A1F9AF0CA'><dir id='8A1F9AF0CA'><tfoot id='8A1F9AF0CA'></tfoot><noframes id='8A1F9AF0CA'>

    • <optgroup id='8A1F9AF0CA'><strike id='8A1F9AF0CA'><sup id='8A1F9AF0CA'></sup></strike><code id='8A1F9AF0CA'></code></optgroup>
        1. <b id='8A1F9AF0CA'><label id='8A1F9AF0CA'><select id='8A1F9AF0CA'><dt id='8A1F9AF0CA'><span id='8A1F9AF0CA'></span></dt></select></label></b><u id='8A1F9AF0CA'></u>
          <i id='8A1F9AF0CA'><strike id='8A1F9AF0CA'><tt id='8A1F9AF0CA'><pre id='8A1F9AF0CA'></pre></tt></strike></i>

          Home / comprehensive / knowledge

          knowledge


          knowledge

          author:explore    Page View:7
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In